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as a ﬁrst-line therapy for VAP. Clinical Cure, utilization data, incidence of adverse 
events, days on mechanical ventilation (MV), ICU days, and LOS in hospital, were 
estimated by combining data from two randomized multicenters, non-inferiority clini-
cal trials of doripenem. Only direct medical costs were considered. Unitary costs of 
MV, ICU, ward days and drugs costs were obtained from the IMSS. The primary 
outcomes were total costs and incremental cost per clinical cure. Sensitivity analyses 
included one-way scenarios and probabilistic analyses (SPA). Results are shown in 
percents, while costs are expressed in Dollars. RESULTS: Doripenem was the least 
expensive treatment in patients with VAP, and in average generated savings of 
$3,374.47/treated patient vs imipenem and $985.04/treated patient vs PT. Doripenem 
dominated PT by being less costly with better clinical cure (72.3% vs 67.8%) Imipenem 
had a clinical cure rate of 72.6% , but an additional cost of $229,152.1/cure. Median 
hospital LOS and mechanical ventilation were signiﬁcantly shorter with doripenem 
than imipenem (22 vs 27 days; P  0.010 and 7 vs 10 days; P  0.034). One-way sen-
sitivity analysis shows that the model is sensitive unitary cost of ICU and MV days 
and clinical cure. The probabilities to be cost-saving are Doripenem 90.1% versus 
Imipenem and 98% versus PT of 1,000 iterations in SPA. CONCLUSIONS: The uti-
lization of Doripenem as a ﬁrst-line therapy in adult patients with VAP is a cost-effec-
tive health intervention and results in considerable savings, compared with imipenem 
and piperazilina-tazobactam due to a signiﬁcantly reduced LOS in the ICU units.
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OBJECTIVES: To determine the most cost-effective alternative for inﬂuenza preven-
tion in Mexican elderly population in a pandemic case scenario. METHODS: A cost-
effectiveness study was performed with Mexican Public Health Institution perspective 
comparing the use of MF59-adjuvanted vaccine (MF59), split vaccine (SPL) and a No 
Vaccination Program Alternative (NOVA). A systematic review of literature was 
designed in order to evaluate the effectiveness of MF59 and SPL measured as hemag-
glutination-inhibition antibody titers against A/H1N1 strain, and to calculate the 
inﬂuenza incidence in a pandemic case scenario. A cost matrix was calculated consider-
ing vaccines, vaccination program, medical visits, inﬂuenza and inﬂuenza related 
complications treatment, hospitalization and intensive care unit cost. Different propor-
tions of patients with inﬂuenza were considered to determine complications related to 
the disease. Use of resources for complication treatment was assumed to be the same 
for every alternative evaluated. A decision tree was designed to simulate the use of 
resources. Results were evaluated with incremental analysis and sensitivity analysis 
of the most uncertain variables (inﬂuenza incidence, vaccine effectiveness, percentage 
of patients developing complications related to inﬂuenza) in order to establish robust-
ness of the study. RESULTS: The use of MF59 represents the lowest cost per patient 
avoiding inﬂuenza or complications related to inﬂuenza when compared with the use 
of SPL or NOVA (MF59: US$25.17; SPL: US$40.50; NOVA: US$127.27) due to 
reduced institutional expenses. The ICER shows that MF59 is a dominant alternative 
in prevention of inﬂuenza and its complications while the sensitivity analysis exhibits 
robustness for the base study. CONCLUSIONS: MF59 is the most cost-effective 
alternative in inﬂuenza prevention for elderly population when a pandemic case sce-
nario in Mexico is simulated. The use of MF59 represents savings estimated in 
US$15.32 and US$102.10 per patient avoiding inﬂuenza when compared to SPL and 
NOVA, respectively.
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OBJECTIVES: In mid 2001 the German Standing Vaccination Committee (STIKO) 
issued a vaccination recommendation for children at risk for pneumococcal diseases. 
This was expanded to all children under the age of two in 2006. In 2009 higher valent 
pneumococcal conjugate vaccines (PCV) will enter the German market. Aim of this 
study is to evaluate cost-effectiveness ratios in children compared to the current stan-
dard immunization (PCV7) in Germany. METHODS: A markov model compares in 
a steady state the historical epidemiological situation (without vaccination) with exist-
ing and upcoming PCV. For all vaccines incidence and cost of pneumococcal infections 
for children (meningitis; bacteraemia; pneumonia and AOM) is considered. Addition-
ally herd immunity effects for adults based on published data are included. In the base 
case the underlying vaccination regime was 31 with a vaccine uptake of 90%. 
RESULTS: In the base case PCV7, PCV10 and PCV13 reduce IPD cases on a popula-
tion level by 4593, 5305, and 6092, respectively. If herd immunity in the unvaccinated 
population is considered, all three PCV are cost-saving. A general vaccination with 
PCV13 dominates the 10- and 7-valent PCV. The validated effect of PCV on naso-
pharyngeal carriage results in herd immunity in non-vaccinated populations. Depend-
ing on vaccine uptake, this effect helps PCV13 to prevent costs of a1.40 (90% uptake) 
and a1.70 (80% uptake) for every Euro spent on vaccination. In sensitivity analyses 
the results were robust to variation of input variables. CONCLUSIONS: Compared 
to other existing PCV, PCV13 is a dominant cost-effective option to prevent pneumo-
coccal diseases. Not only from a medical and epidemiological point of view, but also 
from a health-economic perspective an immediate change from PCV7 to PCV13 
should be considered.
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OBJECTIVES: Seven-valent pneumococcal conjugate vaccine (PCV7) has demon-
strated dramatic public health impact and is considered highly cost-effective. Introduc-
tion of two new pneumococcal conjugate vaccines, 10-valent (PCV10) which is 
conjugated to protein-D, tetanus and diphtheria toxoids and 13-valent (PCV13) which 
is conjugated to CRM197 similar to PCV7, provides coverage to an additional 3 and 
6 serotypes respectively, which is likely to result in further reduction in pneumococcal 
disease. We examined the incremental public health impact and cost-effectiveness of 
two new vaccines compared to PCV7 in Canada. METHODS: A decision-analytic 
model (payer perspective) was developed to estimate impact of PCV13 and PCV10 
vs. PCV7 on invasive pneumococcal disease (IPD), pneumonia, and acute otitis media 
(AOM). We used an epidemiological approach to track serotype speciﬁc incidence, 
disease sequelae, death, and costs. Incidence, disease sequelae, indirect effects, utilities, 
and mortality data were obtained from surveillance systems in the province of Alberta, 
national vital statistics and published literature. Direct effects for PCV13 serotypes 
were assumed similar to those for PCV7 serotypes, whereas PCV10 was assumed to 
be less effective due to lower immunogenicity for the seven common serotypes. A 4-
dose schedule and parity pricing were assumed. RESULTS: When indirect effects due 
to herd immunity were considered for PCV7, PCV7 resulted in less costs and greater 
beneﬁts than PCV10. In the absence of indirect effects, the ICER for PCV10 vs. PCV7 
was $771,938 per QALY. PCV13 was cost saving compared to PCV7, whether indi-
rect effects or direct effects alone were considered. Through direct effects, PCV13 
pediatric vaccination would reduce 60% of IPD in vaccinated children. CONCLU-
SIONS: PCV7 is estimated to be cost saving compared to PCV10. The broader sero-
type coverage of PCV13 would provide additional protection against pneumococcal 
disease and PCV13 is expected to be cost saving.
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OBJECTIVES: To evaluate the cost-effectiveness of micafungin compared to caspo-
fungin in the treatment of systemic Candida infections (SCIs) in Italy, including inva-
sive candidiasis and candidaemia. METHODS: Cost-effectiveness of both echinocandin 
antifungal drugs was estimated using decision analysis. Response to treatment, 
resource utilisation, and costs in the model were derived from a phase 3, head-to-head 
comparative trial. The model includes only data directly related to the treatment of 
the systemic Candida infection over the study duration (a maximum period of 14 
weeks). Transition probabilities were calculated based on the efﬁcacy results from the 
clinical trial. The model’s effectiveness outcome is surviving patients who are success-
fully treated, based on the absence of signs and symptoms, radiographic abnormalities, 
and culture/histologic evidence associated with the fungal infection. In addition, sub-
group analyses were performed to identify cost-effectiveness in several speciﬁc patient 
groups. RESULTS: The total medical treatment costs for the micafungin group were 
a30,758 , which is similar to the total costs for the caspofungin group (a31,923). In 
the micafungin arm 60% of the patients and in the caspofungin arm 58% of the 
patients were successfully treated and alive. Cost-effectiveness ratio of micafungin was 
a51,558, and of caspofungin a55,489 per successfully treated patient. Because the 
costs are lower and the effectiveness is higher for micafungin in comparison with 
caspofungin, micafungin is more cost-effective than caspofungin. Probabilistic sensitiv-
ity and subgroup analysis show that although the difference cannot be considered 
signiﬁcant, due to a large variance, micafungin was the most cost-effective option in 
all subgroup analyses except one. CONCLUSIONS: Costs and effects of micafungin 
compare favourably to those of caspofungin in the treatment of systemic Candida 
infections in Italy. Sensitivity analysis showed that despite the uncertainty in cost-
effectiveness ratio this result is robust. Subgroup analyses showed similar results.
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OBJECTIVES: Pertussis is a highly contagious respiratory disease. Despite an effective 
childhood immunization programme the pertussis incidence among infants remains 
high. As parents are the main transmission vector to infants, their immunization 
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around pregnancy and childbirth (cocooning) could further protect infants. In this 
study cost-effectiveness of cocooning was estimated for The Netherlands. METHODS: 
A decision tree model was developed with a birth cohort and cohort of parents. The 
beneﬁts of pertussis immunization take the direct effect on parents and the indirect 
effect of a reduced transmission to infants into account. The incidence rate based on 
reported cases in The Netherlands has been corrected to take symptomatic unreported 
cases into account. In the sensitivity analysis the impact of the underreporting factor 
on the ICER (Incremental Cost-Effectiveness Ratio) was analyzed. The robustness of 
the estimated ICER was estimated by varying vaccine efﬁcacy, vaccine costs, QALY 
(Quality-Adjusted Life-Year) estimates and indirect beneﬁts. RESULTS: Implementa-
tion of the cocooning immunization strategy is estimated to prevent 57 infant pertussis 
cases per year. From the payer’s perspective, the ICER is estimated at a4,500/QALY 
in the base-case. Sensitivity analysis revealed that the ICER was hardly sensitive to 
vaccine price, indirect beneﬁts and vaccine efﬁcacy. The ICER was however sensitive 
to the underreporting factor, quality of life and cost assumptions for these unreported 
cases. From the societal perspective, the cocooning immunization strategy is estimated 
as cost saving. By decreasing the underreporting factor or QALY losses and costs in 
unreported cases no cost-savings were found anymore, yet the cocooning immuniza-
tion remained highly cost-effective. CONCLUSIONS: The addition of a cocooning 
immunization strategy to the current pertussis immunization programme is likely to 
be cost-effective or even cost-saving from a societal perspective. However the ICER is 
sensitive to the underreporting factor, QALY estimates and costs assumptions in the 
unreported pertussis cases.
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OBJECTIVES: To conduct a cost-effectiveness analysis (CEA) of imiquimod versus 
podophyllotoxin as standard regimen in treatment of genital/perianal warts in Poland. 
METHODS: Our analysis was carried out using a decision model based on the clinical 
effects of imiquimod and podophyllotoxin, obtained from prospective clinical trials. 
Population was deﬁned as adult patients with genital/perianal warts. Total clearing 
warts was assessed as health outcome. Direct medical costs of the analyzed therapies 
were estimated from the perspective of both payers in Poland (National Health Fund 
and patient). Costs of medication and clinic visits were included. Time horizon of the 
analysis was 28 weeks, as during the clinical trial for imiquimod. We assumed the 
mean time of treatment at 13.65 weeks (once a day 3x/week regimen) for imiquimod 
and 4 weeks for podophyllotoxin. Costs and effects were not discounted. RESULTS: 
Probability of total clearing warts was 0.429 for patients treated with imiquimod and 
0.196, for podophyllotoxin teatment. Total costs of imiquimod therapy were esti-
mated at 1121.34 PLN and costs of podophyllotoxin therapy at 218.35 PLN. Incre-
mental cost-effectiveness ratio (ICER) for the comparison of imiquimod versus 
podophyllotoxin was 3865 PLN per gained total clearing warts. CONCLUSIONS: 
Imiquimod is more effective and more expensive than podophyllotoxin in treatment 
of genital/perianal warts. ICER value is below the acceptable threshold, therefore 
imiquimod therapy is considered as cost-effective treatment in Poland.
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OBJECTIVES: To estimate the health outcomes of vaccination with the new 10-valent 
pneumococcal non-typeable Haemophilus inﬂuenzae protein-D conjugate vaccine 
(PH¡D-CV) compared with no vaccination. METHODS: A cross-sectional population-
based model was used to estimate the impact of vaccination over 1-year at vaccine 
steady-state and to perform an incremental cost-effectiveness analysis, comparing 31 
dose vaccination schedule of PH¡D-CV vs no vaccination. Universal massive vaccina-
tion (UMV) for pneumococcal disease is currently not compulsory according to the 
National Vaccination Calendar in Spain. The analysis was performed from the 
National Health System perspective. Input data were obtained from the Ministry of 
Health public database and published regional studies, and was completed by expert 
opinion to validate model assumptions on the vaccination effects of herd-protection 
for invasive disease, serotype replacement, serotype cross-protection and resource use. 
The main clinical outcomes measured were invasive pneumococcal disease (meningitis 
and bacteraemia/sepsis), acute otitis media (AOM), myringotomies and hospitalised 
pneumonia. These were measured by reduction in the disease cases and their associated 
costs. RESULTS: Preliminary results indicate that PHiD-CV could prevent annually 
and for all ages 4.352 hospitalisations (272 meningitis, 2.013 bacteraemia/sepsis and 
2.067 pneumonias), 2.964 myringotomies and 180.361 ambulatory GP-visits for 
AOM, overall reducing disease costs in a34.2M, mainly due to less AOM costs 
(a15.1M). Implementation of PHiD-CV could be a cost-effective intervention com-
pared with no vaccination expressed as cost per QALY gained of a18,597. CONCLU-
SIONS: The analysis predicts that vaccination with PHiD-CV could produce a 
signiﬁcant health improvement and substantial disease cost offset from the National 
Health System perspective when compared to no vaccination. Results support that 
the implementation of PHiD-CV UMV should be considered by Public Health 
decision-makers.
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OBJECTIVES: To compare the cost and efﬁcacy of ritonavir-boosted darunavir 
(darunavir/r) 800/100 mg QD-based triple therapy with combination therapies using 
other boosted protease inhibitors (PI/rs) currently licensed for use in treatment-naïve, 
HIV-1-infected adults in Germany. METHODS: Efﬁcacy was measured by the per-
centage of individuals with plasma HIV RNA  50 copies/mL (the current therapy 
goal) at 48 weeks, based on a systematic review and meta-analysis of clinical trials of 
PI/r-based regimens in treatment-naïve populations. For each PI/r, one-year antiretro-
viral therapy costs (May 2009 Lauer Taxe) were plotted against 48-week efﬁcacy. An 
efﬁciency frontier was constructed by connecting the most economically efﬁcient PI/r-
based regimens. The base-case analysis considered PI/rs with tenofovir-based back-
bone regimens; abacavir-based backbones were considered in scenario analysis. 
RESULTS: In the base-case analysis, darunavir/r was the most efﬁcacious PI/r, with 
an incremental cost-efﬁcacy ratio (ICER) of a20,322 per additional individual with 
virologic response, compared to fosamprenavir/r, the only other point on the efﬁciency 
frontier of PI/r-based initial therapy. All other PI/rs were less efﬁcacious and more 
costly than darunavir/r or fosamprenavir/r, including the two most commonly pre-
scribed PI/rs: atazanavir/r and lopinavir/r. Before the introduction of darunavir/r, 
atazanavir/r was most efﬁcacious but with a higher ICER of a34,244 versus fosam-
prenavir/r. Darunavir/r had an average cost of a20,036 per individual with virologic 
response, compared with a20,976 and a22,861 for atazanavir/r and lopinavir/r, 
respectively. Given a ﬁxed budget of a10 million, darunavir/r successfully treated 499 
individuals, compared with 477 and 437 for atazanavir/r and lopinavir/r, respectively. 
Similar results were obtained in scenario analysis using abacavir-based backbones. 
CONCLUSIONS: Darunavir/r 800/100 mg QD has a lower cost per individual with 
virologic response after 48 weeks than the two most commonly prescribed PI/rs in 
treatment-naïve, HIV-1-infected adults and provides more beneﬁt per additional cost 
than other PI/rs currently used in this population in Germany.
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OBJECTIVES: inﬂuenza vaccination has proven effective in the reduction of inﬂuenza-
like illness (ILI) cases and inﬂuenza-related hospitalisations, drug consumption, 
primary care consultations and deaths in the elderly population. The aim of this study 
is to assess the economic impact in Italy of different prophylactic strategies (vaccina-
tion with a standard vaccine and with the innovative MF59® adjuvated vaccine versus 
no intervention). METHODS: A pharmacoeconomic simulation model has been devel-      
oped. Health economics and demographic data are taken from speciﬁc Italian sources 
and vaccine effectiveness data derived from published. Direct sanitary costs are con-
sidered according to current Italian prices and tariffs. RESULTS: A total of 9,800,000 
of the about 12,000,000 people of 65 years residence in Italy can be considered at 
high risk for inﬂuenza complications due to underlying chronic diseases. Absence of 
vaccination could lead to more than 2 million ILI cases, and 30,000 related deaths. 
The vaccination programme would lead to an estimated 1.5 million ILI cases with a 
standard vaccine and to 1.3 million with the MF59® adjuvated vaccine. The standard 
vaccination strategy could produce a moderate direct cost increase of about a45 
million (4.3%), whereas the adjuvated vaccine could provide an estimated saving of 
about a80 million (7.9%), both compared to the null option. Cost savings are mainly 
related to hospital admissions avoided. The incremental cost-effectiveness ratio (ICER) 
of the standard vaccine vs. no vaccination strategy is of a85.68/ILI avoided, and of 
a4,411.42/death avoided. The strategy based on the MF59® adjuvated vaccine domi-
nates the other two options. CONCLUSIONS: Vaccination with the MF59   ® adjuvated 
vaccine is more effective and cost saving when compared with the standard vaccination 
or no vaccination, thus representing the optimal strategy for the elderly population. 
The standard vaccine, even though a light cost increase, proved to be cost effective 
compared to the null option.
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OBJECTIVES: Comparing the cost-effectiveness of Micafungin (MICA) and Caspo-
fungin (CASPO) for the treatment of systemic candida infections (SCIs) (including 
invasive candidiasis and candidaemia) in Germany. METHODS: A health economic 
decision model is based on a clinical study with a global population. The study was 
a Phase 3 double blind randomized controlled trial comparing MICA versus CASPO. 
Furthermore, German hospitalization and primary medication costs were included in 
